30 August 2016 - The TGA has approved Gilead's combination product for HIV-1 infection Odefsey.

The TGA approved Odefsey (emtricitabine with rilpivirine hydrochloride and tenofovir alafenamide fumarate) on 30 August 2016 for use as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (12 years and older with body weight at least 35 kg) with plasma HIV-1 RNA <= 100,000 copies/mL at the start of therapy. The patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of Odefsey.

Read TGA approval for Odefsey